Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma

Lancet Oncol. 2023 May;24(5):423-425. doi: 10.1016/S1470-2045(23)00123-7. Epub 2023 Mar 31.

Authors

Veronica Mollica¹, Francesco Massari²

Affiliations

¹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. Electronic address: veronica.mollica7@gmail.com.
² Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

PMID: 37011649
DOI: 10.1016/S1470-2045(23)00123-7

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Cell Line, Tumor
Humans
Indenes
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Morphogenesis
Neovascularization, Pathologic / drug therapy
Neovascularization, Pathologic / pathology

Substances

belzutifan
Indenes